Results 171 to 180 of about 1,100,787 (194)

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

New England Journal of Medicine, 2014
Marc Zapatka, Matthias Versele, Peter Lichter   +2 more
exaly  

BRUTON'S TYROSINE KINASE INHIBITORS

2011
ERLANSON DANIEL A, MARCOTTE DOUG, KUMARAVEL GNANASAMBANDAM, FAN JUNFA, WANG DEPING, CUERVO JULIO H, SILVIAN LAURA, POWELL NOEL, BUI MINNA, HOPKINS BRIAN T, TAVERAS ART, GUAN BING, CONLON PATRICK, ZHONG MIN, JENKINS TRACY J, SCOTT DANIEL, LUGOVSKOY ALEXEY A   +16 more
openaire   +8 more sources

Activity of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) in B-Cell Acute Lymphoblastic Leukemia (B-ALL).

Blood, 2012
Ekaterina Kim, Joseph J Buggy
exaly  

Inhibitors of Bruton's Tyrosine Kinase

2011
HONIGBERG LEE, VERNER ERIK, BUGGY JOSEPH J, LOURY DAVID, CHEN WEI, MODY TARAK   +5 more
openaire   +9 more sources

Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies

Annals of the New York Academy of Sciences, 2015
Steven Sun, Fong Clow
exaly  

A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers

British Journal of Clinical Pharmacology, 2017
Patrick F Smith
exaly  

A Phase 1 First-in-Human Pharmacokinetic and Pharmacodynamic Study of JNJ-64264681, a Covalent Inhibitor of Bruton's Tyrosine Kinase

Clinical Pharmacology in Drug Development, 2023
exaly  

Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors

Leukemia and Lymphoma, 2018
Pek Sang Tang, Constantine S. Tam
exaly  

Fungal infection in patients treated with Bruton tyrosine kinase inhibitor—from epidemiology to clinical outcome: a systematic review

Clinical Microbiology and Infection
Arnaud Fekkar, Charles Gibert
exaly  

Acalabrutinib, A Second-Generation Bruton’s Tyrosine Kinase Inhibitor

Recent Results in Cancer Research, 2018
Mathias Witzens-Harig, Katharina Kriegsmann, Mark Kriegsmann   +2 more
exaly